Guests/Speakers
Dr. Ashish Saxena, MD, PhD — Chief of Thoracic Medical Oncology, Weill Cornell Medicine
Wendy Brooks, Voices of Hope Speakers Bureau member living with SCLC
Small cell lung cancer (SCLC) has long been one of the most difficult lung cancers to treat, with chemotherapy serving as the primary option for decades. Wendy Brooks, who is living with limited-stage SCLC, sits down with Dr. Ashish Saxena, Chief of Thoracic Medical Oncology at Weill Cornell Medicine, to discuss how rapidly that landscape is changing.
Asking the Life-Saving Question at Diagnosis
When newly diagnosed with small cell lung cancer, patients often focus on starting treatment as quickly as possible. However, asking about clinical trials at the very first oncology appointment can fundamentally change a patient’s care trajectory.
Dr. Saxena underscores why inquiring about studies upfront is vital:
“Clinical trials aren’t just for sort of a last resort… Actually, the more promising drugs that are being developed are usually moved upfront so that eventually they become the new standard.” — Dr. Ashish Saxena, MD, PhD
Despite the potential benefits, studies indicate that only about 14% of newly diagnosed cancer patients report discussing clinical trials with their care team. Because certain innovative trials require patients to be treatment-naïve before starting therapy, self-advocacy at the initial consultation is critical.
Tracking Quality of Life and Patient-Reported Outcomes
Modern clinical trial design extends beyond evaluating tumor shrinkage and progression-free survival. Researchers increasingly integrate quality of life (QoL) metrics using patient-reported outcomes (PROs) to evaluate how treatments affect daily living.
Through diaries and structured questionnaires, patients report symptoms such as fatigue, cough, shortness of breath, pain, and emotional well-being. These measures allow researchers to identify whether a therapy helps patients feel better faster—sometimes even before visual changes appear on diagnostic scans.
“We as researchers want you to spend more time feeling well and enjoying every day, and the goal is to have meaningful time, not just more time.” — Dr. Ashish Saxena, MD, PhD
Wendy Brooks shared how PROs and open communication directly impacted her care journey. While on her first trial, she experienced a 70% reduction in tumor burden, but severe side effects significantly impacted her quality of life. By discussing these symptoms with her oncologist, she was able to pivot to a different trial that maintained cancer control while drastically improving her daily well-being. Furthermore, Dr. Saxena clarified that reporting side effects does not disqualify patients from a study; rather, it provides vital data needed to manage side effects effectively and guide future care.
Beyond Chemotherapy: New Frontiers in SCLC Treatment
For decades, standard chemotherapy was virtually the only treatment option available for small cell lung cancer. Today, the therapeutic landscape is expanding rapidly through several innovative strategies:
- Immunotherapies: Modern approaches go beyond standard immune checkpoint inhibitors to include novel agents designed to bring immune cells directly to cancer targets.
- Antibody-Drug Conjugates (ADCs): These therapies utilize targeted antibodies to deliver chemotherapy directly to cells expressing specific tumor proteins, minimizing damage to healthy tissue.
- Combination Therapies: Pairing immunotherapies with agents that target tumor angiogenesis (blood vessel growth) shows promising efficacy in ongoing trials.
Early Supportive Care and the Future of Personalized Treatment
Research emphasizes that introducing supportive and palliative care early alongside active treatment—rather than reserving it for end-of-life care—improves patient outcomes. Managing symptoms like pain, nausea, and anxiety enables patients to tolerate treatments longer and maintain better overall health. Accepting early supportive care is not giving up; it is an essential component of comprehensive cancer care.
Looking ahead, scientific advancements are dismantling the view of SCLC as a single uniform disease. Researchers are identifying biological subtypes within small cell lung cancer, opening the door for personalized treatment plans tailored to the specific cellular characteristics of each patient’s tumor.
Resources
- Learn more about clinical trials and how to find one
- LCFA’s First 7 Days: A Roadmap for the Newly Diagnosed
- Understanding Small Cell Lung Cancer
- Small Cell Lung Cancer Treatment Overview: staging, standard-of-care, and FDA-approved treatments
- Living With Lung Cancer: Ask Me Anything Series: survivor-led podcast strips away the clinical jargon to reveal what living with lung cancer really looks like.
- Find a Clinical Trial: Small Cell Lung Cancer to search for:
- First-line SCLC trials combining a new agent with standard-of-care chemotherapy
- Immunotherapy maintenance trials
- Academic-center consultations for newly diagnosed patients
